je.st
news
Tag: fda
Mesothelioma Immunotherapy Vaccine Receives Orphan Drug Designation From FDA, Baron & Budd Reports
2015-04-29 04:58:10| drugdiscoveryonline Home Page
The mesothelioma law firm of Baron & Budd reports the U.S
Tags: reports
drug
receives
designation
PharmaEngine Announces Merrimack Completed MM-398 (PEP02) New Drug Application Submission To U.S. FDA
2015-04-29 03:56:16| drugdiscoveryonline Home Page
PharmaEngine, Inc. recently announced that its licensing partner, Merrimack Pharmaceuticals, Inc. has completed the rolling submission of the New Drug Application (NDA) for MM-398 (irinotecan liposome injection) to the U.S
Tags: us
application
completed
drug
Lilly's CYRAMZA (ramucirumab) Receives Fourth FDA Approval
2015-04-27 05:33:40| drugdiscoveryonline Home Page
Eli Lilly and Company (NYSE: LLY) has received its fourth U.S. Food and Drug Administration (FDA) approval for CYRAMZA® (ramucirumab). CYRAMZA (ramucirumab injection 10 mg/mL solution) is now also indicated in combination with FOLFIRI (irinotecan, folinic acid, and 5-fluorouracil) chemotherapy for the treatment of patients with metastatic colorectal cancer (mCRC) with disease progression on or after prior therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine.
Tags: fourth
approval
receives
fda
FDA records: 5th death associated with Essure
2015-04-25 23:22:55| Real Estate - Topix.net
Opponents of a controversial development in Carmel Valley collected enough referendum petition signatures to force the San Diego City Council to either rescind its approval of the project or put the issue to voters, the City Clerk's Office announced Friday. More than 60,000 signatures were turned in by opponents of the 23.6-acre project, far more than the 34,000-plus needed to qualify.
New FDA Draft Guidance: eCTD Is Coming to Promotional SubmissionsAre You Ready?
2015-04-23 16:57:36| drugdiscoveryonline Home Page
Date: Friday, May 15, 2015 Time:1pm - 2:30pm EDT Duration: 90 Minutes - Online $299 - Introductory Rate
Sites : [95] [96] [97] [98] [99] [100] [101] [102] [103] [104] [105] [106] [107] [108] [109] [110] [111] [112] [113] [114] next »